Mechanism of action of lenalidomide in hematological malignancies

Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das, Amit K. Verma

Research output: Contribution to journalArticle

257 Citations (Scopus)

Abstract

Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.

Original languageEnglish (US)
Article number36
JournalJournal of Hematology and Oncology
Volume2
DOIs
StatePublished - 2009

Fingerprint

Hematologic Neoplasms
Thalidomide
Chromosome Deletion
Myelodysplastic Syndromes
Immunologic Factors
Multiple Myeloma
Pharmaceutical Preparations
Nervous System
Immune System
Signal Transduction
Extremities
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Medicine(all)

Cite this

Mechanism of action of lenalidomide in hematological malignancies. / Kotla, Venumadhav; Goel, Swati; Nischal, Sangeeta; Heuck, Christoph; Vivek, Kumar; Das, Bhaskar; Verma, Amit K.

In: Journal of Hematology and Oncology, Vol. 2, 36, 2009.

Research output: Contribution to journalArticle

@article{dda8887ebc6e4eb68ee26877369bf887,
title = "Mechanism of action of lenalidomide in hematological malignancies",
abstract = "Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.",
author = "Venumadhav Kotla and Swati Goel and Sangeeta Nischal and Christoph Heuck and Kumar Vivek and Bhaskar Das and Verma, {Amit K.}",
year = "2009",
doi = "10.1186/1756-8722-2-36",
language = "English (US)",
volume = "2",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Mechanism of action of lenalidomide in hematological malignancies

AU - Kotla, Venumadhav

AU - Goel, Swati

AU - Nischal, Sangeeta

AU - Heuck, Christoph

AU - Vivek, Kumar

AU - Das, Bhaskar

AU - Verma, Amit K.

PY - 2009

Y1 - 2009

N2 - Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.

AB - Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.

UR - http://www.scopus.com/inward/record.url?scp=69949096727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949096727&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-2-36

DO - 10.1186/1756-8722-2-36

M3 - Article

C2 - 19674465

AN - SCOPUS:69949096727

VL - 2

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 36

ER -